A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
2014 · PLoS ONE · 51 citations
https://doi.org/10.1371/journal.pone.0115161
C
Carly M. Bliss
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
52
Papers
3.7K
Citations
28
h-index
36
i10-index
Carly M. Bliss is an academic researcher from University of Oxford. The author has contributed to research in topics: Malaria Research and Control & Mosquito-borne diseases and control & vaccines and immunoinformatics approaches. The author has an h-index of 28, co-authored 45 publications.
ORCID: 0000-0002-5117-1016Papers by this author
worksAssessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
2018 · Scientific Reports · 43 citations
https://doi.org/10.1038/s41598-018-21630-4
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
2024 · EBioMedicine · 14 citations
https://doi.org/10.1016/j.ebiom.2024.105153
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
2025 · The Lancet Microbe · 10 citations
https://doi.org/10.1016/s2666-5247(24)00084-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat